Lina Nasser Al Tamimi
@zu.edu.jo
Clinical Pharmacy Department/ Faculty of Pharmacy
Zarqa University
RESEARCH INTERESTS
Supplementary Therapy, Clinical Pharmacy, Pharmaceutical Nutritional Support, Drug-Supplement Interaction, Diabetology, Clinical Biochemistry
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Zainab Zakaraya, Mohammad Abu Assab, Lina N. Tamimi, Nida Karameh, Mohammad Hailat, Laila Al-Omari, Wael Abu Dayyih, Omar Alasasfeh, Mohammad Awad, and Riad Awad
MDPI AG
The two main classifications of antidepressant medications are selective norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs). Out of the available choices, selective serotonin reuptake inhibitors (SSRIs) have emerged as the most commonly prescribed option. The class demonstrates a greater degree of diversity in its structural characteristics in contrast to its neurochemical effects. Nevertheless, it is important to acknowledge that the chemical composition of a drug within this specific class does not carry substantial significance in the selection process. A comprehensive analysis of the pharmacodynamic and pharmacodynamic properties of antidepressant drugs proves advantageous for clinicians and managed care providers responsible for selecting preferred selective serotonin reuptake inhibitors (SSRIs) from a roster of authorized medications. The physicochemical characteristics, which possess considerable significance, are frequently disregarded except during the drug development stage. Pharmacodynamic properties refer to the physiological and biochemical effects that drugs exert on the human body. It is noteworthy that the inclusion of selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) in a comprehensive depression management protocol may demonstrate enhanced effectiveness in clinical environments as opposed to controlled trials.
Deema Jaber, Abeer Al Shihab, and Lina N. Tamimi
Hindawi Limited
Background. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to manage pain, including chronic pain conditions. However, their prolonged use is associated with significant risks, particularly gastrointestinal (GI) adverse events. This study aimed to evaluate the effectiveness and safety of a pharmacist-managed deprescribing program for NSAIDs in a Jordanian outpatient population. Methods. A convenience sample of 100 participants who had been using NSAIDs for pain management was recruited. Participants underwent a structured deprescribing intervention in collaboration with physicians. Various effectiveness and safety outcomes were assessed before and after deprescribing. Descriptive statistics and chi-square test were used for data analysis. Results. The majority of participants reported chronic pain conditions, with rheumatoid arthritis (24%) and osteoarthritis (22%) being the most prevalent. Ibuprofen (28%) and diclofenac (22%) were the most commonly used NSAIDs. The deprescribing program was associated with a significant reduction in heartburn, stomach ulcer, kidney problems and fluctuation in blood pressure readings (p<0.05), and pain exacerbation. Notably, the reduction in pain exacerbation was evident (p=0.003) in the 4-month follow-up. Conclusion. A pharmacist-managed NSAIDs deprescribing program demonstrated effectiveness in reducing the risk of GI adverse events and fluctuation in blood pressure readings without causing harm during a short-term follow-up. These findings support the feasibility of implementing such programs in outpatient settings. Further long-term investigations are necessary to confirm these results.
L. Tamimi, Z. Zakaraya, M. Hailat, W. Abu Dayyih, E. Daoud, A. abed, M. Saadh, B. Majeed, H. Abumansour, A. Aburumman,et al.
OBJECTIVE
Limitations and side effects associated with current anti-diabetic treatments have necessitated the search for new therapeutic alternatives. This study aimed to explore the combined use of resveratrol (RVT) and established anti-diabetic drug pioglitazone (PGZ) against streptozotocin (STZ)-induced diabetes mellitus (DM).
MATERIALS AND METHODS
STZ was supplemented daily to Sprague-Dawley rats to induce DM. The synergistic effect of the RVT (20 mg/kg) and PGZ (0.65 mg/kg) on DM complications was evaluated after 8 weeks of treatment. Biochemical analyses were performed to evaluate the effectiveness of our treatment on glucose level, insulin sensitivity, lipid disturbances, oxidative mediators and inflammatory markers.
RESULTS
STZ induced DM onset that is accompanied with elevated diabetic markers, lipid disturbances, remarkable oxidative damage and hyper-inflammation. The PGZ+RVT combination has the best effect as illustrated by significant (p < 0.05) decreases in fasting blood glucose, insulin, HbA1c and HOMA-IR levels. This combination attenuated (p < 0.05) lipid disturbances and their associated elevated atherogenic biomarkers. At the same time, treatments with PGZ+RVT exhibited an anti-inflammatory effect as it attenuated the increase in inflammatory parameters (CRP, TNF-α, IL-6). Also, it restored total antioxidant capacity and peroxisome proliferator-activated receptor (PPARg) levels that decreased by STZ-DM induction.
CONCLUSIONS
This study provides PGZ+RVT as promising DM therapeutic alternative. This synergistic combination alleviates most of DM-related complications and insulin resistance.
Wael Abu Dayyih, Mohammad Hailat, Tayel A. Al Hujran, Mousa Magharbeh, Zainab Zakaraya, Lina Al Tamimi, Aseel M. Aburumman, Hamza Abumansour, and Riad Awad
Open Science Publishers LLP
Azo dyes account for 70% of dye chemistry, and their importance may grow in the future. Empagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor. SGLT2 transporters are primarily responsible for glucose reabsorption in the kidney. In 2014, empagliflozin was approved for medical use in the United States and the European Union. With over 4 million prescriptions in 2019, it was the 146th most commonly prescribed medication in the United States in 2019. The spectrophotometric determination of empagliflozin is described using coupling agents such as 3-chloro-4-nitroaniline or sulfanilamide. These methods are straightforward and are based on the reaction of empagliflozin with diazotized products of 3-chloro-4-nitroaniline or sulfanilamide to produce colored azo dyes with absorption maxima at 470 and 480 nm. Empagliflozin was linear from 1.2 to 26.6 µgml −1 or 0.8 to 20.4 µgml −1 when combined with diazotized 3-chloro-4-nitroaniline or sulfanilamide, respectively. Empagliflozin’s molar absorptivity and Sandell’s sensitivity to 3-chloro-4-nitroaniline or sulfanilamide azo dyes were 3.179 × 10 4 l mol −1 cm −1 or 4.367 × 10 4 l mol −1 cm −1 and 1.149 × 10 −2 µgcm −2 or 8.368 × 10 −3 µgcm −2 , respectively. The formed colored azo dyes are stable for more than 12 hours. The optimal reaction conditions and other analytical parameters are assessed. Foreign organic compound interference has been studied. The method has been successfully used to determine empagliflozin in pharmaceutical samples.
Ramadan Al-Shdefat, Israa Al-Ani, Lina Tamimi, Riad Awad, Walid Abu Rayyan, and Wael Abu Dayyih
Springer Science and Business Media LLC